In this week's FiercePharmaAsia wrap-up, Takeda and VC Lightstone have joined forces in forming a neuroscience startup, China's cancer research is narrowing the U.S. lead, Sun's Halol plant was hit by FDA notice again, and more.
Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the development of a more advanced version for people with Type 1 diabetes.
